Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email
R3i editorial
14 December 2016

Prof. Jean Charles Fruchart, Prof. Michel Hermans, Prof. Pierre Amarenco
SPPARM?: more than one way to tackle residual riskRead more...

Atherogenic dyslipidaemia, the combination of elevated triglycerides and low plasma concentration of high-density lipoprotein cholesterol (HDL-C), is a contributing factor to residual cardiovascular risk. Until recently, much of the focus for therapeutic intervention has been on HDL-C, given extensive epidemiologic evidence that low HDL-C is a risk factor for cardiovascular disease.
However, the consistent failure of clinical trials testing numerous approaches to raising HDL-C, or its major apolipoprotein, apoA-I, most recently reported for apoAI Milano at the American Heart Association Scientific Sessions, highlights the need for new thinking...
PCSK9 and Atherosclerosis
Downloadable slidekit
PCSK9 downloadable slidekit
Created by Professors Jean Davignon (Vice-President of the R3i foundation), Jean-Charles Fruchart (President of R3i) and Michel Hermans (R3i General Secretary), the latest downloadable deck of 242 slides discusses the potential role for anti-PCSK9 mAbs in the future management of cardiovascular disease.
landmark study
13 December 2016

GLAGOV: benefit with intensive LDL-lowering, but residual risk persists Read more...

GLAGOV evaluated the impact of additional LDL-C lowering on progression of coronary atherosclerosis in patients with established coronary disease who were receiving optimized, stable background statin therapy. The results of the study show that further LDL-C lowering with the PCSK9 inhibitor evolocumab (to a value...
focus on...
13 December 2016

PROMINENT (Pemafibrate to Reduce cardiovascular OutcoMes by reducing triglycerides IN diabetic patiENTs): A rationale Read more...

Despite best evidence-based management, including well controlled low-density lipoprotein cholesterol (LDL-C) levels, patients at high cardiovascular (CV) risk continue to experience (recurrent) events. A proportion of this residual CV risk is indisputably due to a lipid/lipoproteins risk component (1). There are a number of lines...
recent publication

News from American Heart Association Scientific Sessions 2016, 11-15 November, New Orleans, USARead more...

Lipids were very much in the news at this year’s...
recent publication

Residual cardiovascular risk in a real-world settingRead more...

One in eight very high risk patients remain at high...
recent publication

Triglycerides:HDL ratio predicts worse outcomes after acute ischaemic strokeRead more...

A lower triglycerides/high-density lipoprotein cholesterol ratio (TG/HDL-C) was a predictor...
recent publication

Economic benefits of targeting both cholesterol and triglyceridesRead more...

Results from this study indicate economic benefit from treating diabetic...
recent publication

Dyslipidaemia may precede peripheral insulin resistanceRead more...

Results from this Chinese study reinforce the importance of targeting...
recent publication

Peripheral artery disease associated with increased cardiovascular riskRead more...

In this analysis of the PreterAx and DiamicroN modified-release controlled...

What is residual risk?

Residual risk of vascular events persisting in patients at treatment goals according to current standards of care or failing to meet goals, including risk related to dyslipidemia, high blood pressure, hyperglycemia, systemic inflammation and unhealthy lifestyles.

What is the Initiative ?

The R3i, a worldwide, academic, multidisciplinary non-profit organization, aims to successfully address the excessively high risk of macro- and micro-vascular complications in patients with atherogenic dyslipidemia, characterised by elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol and unaddressed by current standards of care.